ATE483462T1 - Verwendung der epothilons zur behandlung der krebs - Google Patents

Verwendung der epothilons zur behandlung der krebs

Info

Publication number
ATE483462T1
ATE483462T1 AT99910257T AT99910257T ATE483462T1 AT E483462 T1 ATE483462 T1 AT E483462T1 AT 99910257 T AT99910257 T AT 99910257T AT 99910257 T AT99910257 T AT 99910257T AT E483462 T1 ATE483462 T1 AT E483462T1
Authority
AT
Austria
Prior art keywords
epothilones
treat cancer
epothilone
treatment
certain
Prior art date
Application number
AT99910257T
Other languages
German (de)
English (en)
Inventor
Terence O'reilly
Markus Wartmann
Manuel Litchman
Pamela Cohen
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Priority claimed from PCT/EP1999/001147 external-priority patent/WO1999043320A1/en
Application granted granted Critical
Publication of ATE483462T1 publication Critical patent/ATE483462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT99910257T 1998-02-25 1999-02-23 Verwendung der epothilons zur behandlung der krebs ATE483462T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones
PCT/EP1999/001147 WO1999043320A1 (en) 1998-02-25 1999-02-23 Use of epothilones for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE483462T1 true ATE483462T1 (de) 2010-10-15

Family

ID=27451759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910257T ATE483462T1 (de) 1998-02-25 1999-02-23 Verwendung der epothilons zur behandlung der krebs

Country Status (4)

Country Link
US (1) US6302838B1 (enExample)
JP (1) JP2011173928A (enExample)
AT (1) ATE483462T1 (enExample)
DE (1) DE69942827D1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
IL156988A0 (en) * 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
PL207197B1 (pl) * 2001-02-27 2010-11-30 Novartis Ag Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia
EP1372650B1 (en) * 2001-03-19 2008-11-19 Novartis AG Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
ES2279139T3 (es) * 2002-10-15 2007-08-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo.
CA2526285A1 (en) * 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
EP1641449A1 (en) * 2003-06-27 2006-04-05 Novartis AG Cancer treatment with epothilones
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
CA2744713A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
MX2011010045A (es) * 2009-03-25 2011-10-11 Novartis Ag Composicion farmaceutica que contiene un farmaco y siarn.
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.

Also Published As

Publication number Publication date
JP2011173928A (ja) 2011-09-08
US6302838B1 (en) 2001-10-16
DE69942827D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
MXPA03010909A (es) Derivados de epotilona.
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
EP1481077A4 (en) MITOTIC KINESINE HEMMER
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
BR0214787A (pt) Compósitos elastoméricos, combinações de elastÈmeros e métodos
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
EE200000077A (et) Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
ATE368649T1 (de) Cyanoguanidin prodrugs
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
DE60312988D1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
DE60106947D1 (de) Oxindolderivate
BRPI0407681A (pt) sulfamatos de d-homoestra-1,3,5(10)-trien-3-ila 2-substituìdos ativos antitumorais
ATE480237T1 (de) Tumorhemmende nitroacridin-zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056453

Country of ref document: EP